XOMA Royalty entered an agreement to acquire Generation Bio for $4.2913 per share in cash and to issue contingent value rights tied to net cash, lease savings and potential milestone/royalty proceeds from Generation Bio’s collaborations, including its license with Moderna. The deal brings Generation Bio’s cell‑targeted lipid nanoparticle (ctLNP) delivery platform into XOMA Royalty’s portfolio and creates potential milestone and royalty streams for the acquirer.